Electra Therapeutics

Electra Therapeutics develops antibody therapies targeting the SIRP receptor to treat immunology and cancer, specifically life-threatening sHLH.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2026
Stage of Initial Investment
Series B
Initial Investment Year
2022
Electra Tx Hover Image